NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Code Rebel Corporation (“Code Rebel” or the “Company”) (NASDAQ: CDRB) between August 17, 2015 and May 5, 2016.

You are hereby notified that a securities class action has commenced in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/code-rebel-corporation.

The complaint alleges that, throughout the class period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Code Rebel’s financial statements contained errors concerning its assets and financial condition; and (2) as a result of the foregoing, Code Rebel’s public statements were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On May 6, 2016, trading of Code Rebel stock was suspended following an Order issued by the U.S. Securities and Exchange Commission. According to the SEC, “there is a lack of accurate information concerning the securities of Code Rebel…because of questions regarding the accuracy of statements in CDRB’s Forms 10-Q for the quarters ended June 30, 2015 and September 30, 2015, and the Form 10-K for the year ending December 31, 2015, concerning the company’s assets and financial condition.”

If you suffered a loss in Code Rebel you have until July 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/code-rebel-corporation.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440318

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of HCP, Inc. (“HCP” or “the Company”) (NYSE: HCP) between March 30, 2015 and February 8, 2016. You are hereby notified that a class action lawsuit has commenced in the USDC for the Northern District of Ohio. To get more information go to:

http://www.zlk.com/pslra/hcp

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that HCP violated securities laws by failing to disclose during the class period that one of the Company’s major clients, ManorCare, was engaged in rampant billing fraud that may have generated more than $6 billion in false claims for reimbursement, and that the value of HCP’s interest in ManorCare was questionable.

On April 21, 2015, HCP disclosed that the U.S. Department of Justice had intervened in whistleblower lawsuits. Then on May 5, 2015, HCP disclosed a recorded $478 million non-cash impairment charge related to certain of its lease arrangements with ManorCare. Then on February 9, 2016, HCP disclosed that its equity stake in ManorCare had been written down to zero, and that it had taken an $836 million non-cash impairment on its ManorCare lease assets and placed all of its ManorCare real estate assets on a “Watch List.”

If you suffered a loss in HCP you have until July 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440317

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Deutsche Bank AG (“Deutsche Bank” or the “Company”) (NYSE: DB) between April 15, 2013 and April 29, 2016.

You are hereby notified that a securities class action has commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Deutsche Bank securities between April 15, 2013 and April 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/deutsche-bank-ag.

The complaint alleges that defendants throughout the Class Period issued false and misleading statements to investors and/or failed to disclose that: (1) Deutsche Bank has serious and systemic failings in its controls against financing terrorism, money laundering, aiding against international sanctions, and committing financial crimes; (2) Deutsche Bank’s internal control over financial reporting and its disclosure controls and procedures were not effective; and (3) as a result of the foregoing, defendants’ statements about Deutsche Bank’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Deutsche Bank you have until July 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/deutsche-bank-ag.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440316

YOUNGSVILLE, LA / ACCESSWIRE / May 23, 2016 / RedHawk Holdings Corp. (OTC: IDNG) (“RedHawk” or the “Company”) announced today its financial results for the three and nine month periods ended March 31, 2016.

For the three month period ended March 31, 2016, the Company reported a net loss from continuing operations of $653,811, $0.00 per share, on revenues of $9,750. This compares to a net loss from continuing operations of $20,883, $0.00 per share, on nil revenues for the same three-month period ended March 31, 2015. The increase in the net loss was primarily attributable to one-time professional fees incurred in connection with RedHawk’s recent business acquisitions, the repurchase of approximately 18 million shares of the Company’s common stock, the pursuit of various claims against its former legal and accounting professionals and the pursuit of claims against a former officer of the Company and certain private equity investors. During the third quarter ended March 31, 2016, the Company also experienced an increase in its management fees over the comparable 2015 three-month period as it assembled its executive management team in the United States and the United Kingdom and incurred a one-time consultancy fee of $174,000 in connection with the non-compete agreement entered into with Scarlett Pharma LTD.

For the nine month period ended March 31, 2016, the Company reported a net loss from continuing operations of $788,924, $0.00 per share, on revenues of $19,700, as compared to a net loss of $124,163, $0.00 per share, on minimal revenues for the same nine month period ended March 31, 2015. As with the three-month period ended March 31, 2016, the increase in the net loss from continuing operations resulted primarily from higher one-time professional fees and higher management fees.

Commenting on the three and nine month results, the Company said it had completed the anticipated recapitalization of its balance sheet. It said it is now focused on restructuring its short term-debt in preparation for the commencement of revenue activity and further strategic expansion in its pharmaceutical and medical device business units. Revenues in the pharmaceutical and medical device business units are expected to accelerate at the beginning of the Company’s new fiscal year.

Additionally, the Company said it expects to receive and complete the regulatory testing of the first Centri Controlled Entry System (“Centri”) before its fiscal year end on June 30, 2016. The first unit will be delivered to, assembled and tested at the Company’s newly established RedHawk Innovation Center at the Louisiana State University Innovation Park, a 200 plus acre university research park. After the Company receives regulatory approval from the U.S. Food & Drug Administration, the Company said it expects to begin marketing Centri into the corrections and energy business sectors.

About RedHawk Holdings Corp.

RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical – Advanced Bleeding Control, the Disintegrator™ Insulin Needle Destruction Unit, the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk’s real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company’s financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.

Cautionary Statement Regarding Forward Looking Statements

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.

Media Contact:

Julie Calzone
(337) 235-2924
jcalzone@calzone.com

Company Contacts:

Daniel J. Schreiber, CEO
(858) 509-8800
dan@redhawkholdingscorp.com

Thomas J. Concannon, COO
(908) 625-7811
tom.concannon@redhawkholdingscorp.com

G. Darcy Klug, CFO
(337) 269-5933
darcy.klug@redhawkholdingscorp.com

SOURCE: RedHawk Holdings Corp.

ReleaseID: 440315

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The Stock Expert is issuing a report on four stocks that are performing well today. XNPT, CLRB, BBEP and XGTI are on high volume alert. Continue reading to find out why. – To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.

Xenoport, Inc. (NASDAQ: XNPT) XNPT is a biopharmaceutical company that focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders in the United States.

Shares of XNPT are trading higher today by over 56.50%, soaring to $6.89 in share price off massive volume after announcing that Arbor Pharmaceuticals will buy the biopharmaceutical company in a deal valued at around $467 million.

Under the terms of the deal, Arbor will buy all of XenoPort’s outstanding shares for $7.03 a share.

Not long after the announcement, Levi & Korsinsky, LLP announced an investigation as to whether the sale of Xenoport is fair at $7.03 per share for the shareholders.

We will continue to follow XNPT as the news comes in to see what the investigation digs up.

Subscribe Free To Receive Alerts Like These Sent To Your Inbox Get Your Free Membership Now.

Cellectar Biosciences, Inc. (NASDAQ: CLRB) The company is a biopharmaceutical company, develops compounds for the treatment, diagnosis, and imaging of cancer.

After nosediving through most of 2016, over the last two trading days, CLRB has not only seen a massive spike in share price but has also been the beneficiary of a surge in volume.

Shares of CLRB were up 393% from its 52 week low just 3 trading days ago, after hitting $4.93 for its HOD (high of day) and is still up over 12.75% on the day.

The stock jumped 200% after announcing that it received patent identification numbers for cancer targeting drug vehicles, the presumed catalyst for the quick rise in share price.

This is great news for the struggling biotech, however, with an RSI (relative strength index) of over 72, CLRB is showing signs of a slight pull back, already giving back over $1.00 in share price intra-day today.

Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.

Breitburn Energy Partners LP (NASDAQ: BBEP) The company is an independent oil and gas partnership that acquires, exploits, and develops oil, natural gas liquids (NGLs), and natural gas properties in the United States.

After shares of BBEP fell off a cliff in mid-May, after announcing that the company filed Chapter 11, the stock was trading at 52 week lows.

However, since then, the stock has been the beneficiary of some great technicals and has regained over half of its losses and has traded higher in each of the last 4 trading days.

Shares are trading higher today by over 52% making stronger gains through the day, off massive volume, and with an RSI (relative strength index) of just over 31, there’s still plenty of room for BBEP to trade higher before hitting overbought levels.

Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.

xG Technology, Inc. (NASDAQ: XGTI) The company engages in the development of communication technologies for wireless networks worldwide.

Shares of XGTI are trading higher today by almost 100% off over 17 times its average volume.

After hitting highs of $0.2890, XGTI has cooled off a bit, however, is still holding on to near triple digit gains in just one day.

While XGTI’s RSI (relative strength index) is over bought at 73, We look forward to see what XGTI can do this week with this kind of momentum.

NASDAQ Stock Alerts: Check Them Out Here To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.

About TheStockExpert.com

The Stock Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.

To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word “STOCKEXPERT”.

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The Stock Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The Stock Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit TheStockExpert.com/disclaimer website for a more detailed discussion of risks and disclosures.

Contact:

Justin Skibinski
The Stock Expert
info@thestockexpert.com

SOURCE: The Stock Expert

ReleaseID: 440314

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Resource America, Inc. (NASDAQ: REXI) stock prior to May 23, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Resource America, Inc. (NASDAQ: REXI) to C-III Capital Partners LLC for $9.78 in cash per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/resource-america-rexi or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440311

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased American Capital, Ltd. (NASDAQ: ACAS) stock prior to May 23, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of American Capital to Ares Capital Corporation (NASDAQ: ARCC) for $6.41 in cash and 0.483 of an Ares Capital share for each share of American Capital stock held. In a separate transaction, American Capital is selling American Capital Mortgage Management, LLC for $2.45 per share to American Capital Agency Corp. The combined transactions represent a value of approximately $17.40 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/american-capital-acas or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440309

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased XenoPort, Inc. (NASDAQ: XNPT) stock prior to May 23, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of XenoPort, Inc. to Arbor Pharmaceuticals, LLC. Under the terms of the transaction, XenoPort shareholders will receive $7.03 in cash for each share of XenoPort stock they own. To learn more about the action and your rights, go to: http://zlk.9nl.com/xenoport-xnpt or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440310